Pentraxin 3 serum levels in wet-type age-related macular degeneration
نویسندگان
چکیده
منابع مشابه
Wet Age Related Macular Degeneration
Age related macular degeneration (AMD) is the leading cause of blindness in the developed countries. Approximately 8 million people in America have AMD and the number of advanced AMD is likely to rise by 50% by year 2020 due to the projected increase in the number of elderly people (Friedman et al., 2004). AMD is a condition of significant morbidity in terms of both physical and mental health (...
متن کاملImaging of Wet Age-Related Macular Degeneration
All images are acquired on a Spectralis device from Heidelberg Engineering. Image courtesy of Dr. (med) Ke-nan Damer, Birmingham Midlands Eye Centre, Sandwell and West Birmingham NHS Trust. Fig. 1. a Shows the macula of a left eye with reduced foveal reflectivity on the infra-red picture, which is due to intra-retinal fluid caused by choroidal neovascularization (CNV) related to wet AMD. In b ,...
متن کاملSerum levels of lipid metabolites in age-related macular degeneration.
Age-related macular degeneration (AMD) is a neurodegenerative disease that causes adult-onset blindness. There are 2 forms of this progressive disease: wet and dry. Currently there is no cure for AMD, but several treatment options have started to emerge making early detection critical for therapeutic success. Analysis of the eyes of Abca4(-/-)Rdh8(-/-) mice that display light-induced retinal de...
متن کاملFocal macular electroretinograms in eyes with wet-type age-related macular degeneration.
PURPOSE To study the properties of the focal macular electroretinograms (fmERGs) in eyes with untreated wet-type age-related macular degeneration (AMD). METHODS fmERGs were recorded from 157 eyes of 157 consecutive patients with untreated wet-type AMD (113 men, 44 women; age, 71.3 +/- 8.0 years). The fmERGs were recorded under direct fundus observation using a modified infrared fundus camera ...
متن کاملIndividualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration
Individualized treatment regimens may reduce patient burden with satisfactory patient outcomes in neovascular age-related macular degeneration. Intravitreal anti-VEGF drugs are the current gold standard. Fixed monthly injections offer the best visual outcome but this regimen is not commonly followed outside clinical trials. A PRN regimen requires monthly visits where the patient is treated in t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Analytical Research in Clinical Medicine
سال: 2016
ISSN: 2345-4970
DOI: 10.15171/jarcm.2016.001